We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Humana (HUM) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
Humana (HUM - Free Report) closed at $440.99 in the latest trading session, marking a -0.9% move from the prior day. This change lagged the S&P 500's 0.79% loss on the day. At the same time, the Dow lost 1.07%, and the tech-heavy Nasdaq lost 2.71%.
Heading into today, shares of the health insurer had lost 11.83% over the past month, lagging the Medical sector's loss of 0.35% and the S&P 500's gain of 4.16% in that time.
Investors will be hoping for strength from Humana as it approaches its next earnings release, which is expected to be August 2, 2023. On that day, Humana is projected to report earnings of $8.88 per share, which would represent year-over-year growth of 2.42%. Meanwhile, our latest consensus estimate is calling for revenue of $25.82 billion, up 9.12% from the prior-year quarter.
HUM's full-year Zacks Consensus Estimates are calling for earnings of $28.28 per share and revenue of $102.16 billion. These results would represent year-over-year changes of +12.04% and +10%, respectively.
Any recent changes to analyst estimates for Humana should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.04% higher. Humana currently has a Zacks Rank of #2 (Buy).
Looking at its valuation, Humana is holding a Forward P/E ratio of 15.73. This valuation marks a discount compared to its industry's average Forward P/E of 16.13.
It is also worth noting that HUM currently has a PEG ratio of 1.16. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - HMOs stocks are, on average, holding a PEG ratio of 1.13 based on yesterday's closing prices.
The Medical - HMOs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 76, which puts it in the top 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Humana (HUM) Dips More Than Broader Markets: What You Should Know
Humana (HUM - Free Report) closed at $440.99 in the latest trading session, marking a -0.9% move from the prior day. This change lagged the S&P 500's 0.79% loss on the day. At the same time, the Dow lost 1.07%, and the tech-heavy Nasdaq lost 2.71%.
Heading into today, shares of the health insurer had lost 11.83% over the past month, lagging the Medical sector's loss of 0.35% and the S&P 500's gain of 4.16% in that time.
Investors will be hoping for strength from Humana as it approaches its next earnings release, which is expected to be August 2, 2023. On that day, Humana is projected to report earnings of $8.88 per share, which would represent year-over-year growth of 2.42%. Meanwhile, our latest consensus estimate is calling for revenue of $25.82 billion, up 9.12% from the prior-year quarter.
HUM's full-year Zacks Consensus Estimates are calling for earnings of $28.28 per share and revenue of $102.16 billion. These results would represent year-over-year changes of +12.04% and +10%, respectively.
Any recent changes to analyst estimates for Humana should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.04% higher. Humana currently has a Zacks Rank of #2 (Buy).
Looking at its valuation, Humana is holding a Forward P/E ratio of 15.73. This valuation marks a discount compared to its industry's average Forward P/E of 16.13.
It is also worth noting that HUM currently has a PEG ratio of 1.16. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - HMOs stocks are, on average, holding a PEG ratio of 1.13 based on yesterday's closing prices.
The Medical - HMOs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 76, which puts it in the top 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.